Sutro Biopharma Inc. (STRO) Prices 11M Share Common Offering at $7.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Sutro Biopharma Announces Pricing of $85.3 Million Public Offering
May 11, 2020 11:55 PM EDTSOUTH SAN FRANCISCO, Calif., May 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $7.75 per share. The gross proceeds from this offering are expected to be approximately $85.3 million, before deducting underwriting discounts and... More
